For Doctors in a Hurry
- Researchers investigated whether endovascular therapy reduces symptom severity in patients with post-thrombotic syndrome and iliac-vein obstruction.
- This randomized trial assigned 225 patients to receive either endovascular stent placement with antithrombotic therapy plus standard care or standard care alone.
- At six months, the endovascular group had a 2.0-point lower Venous Clinical Severity Score (P=0.001) but higher bleeding rates (11.6% versus 3.6%, P=0.03).
- The authors concluded that endovascular therapy decreases post-thrombotic syndrome severity and improves quality of life despite increased bleeding risks.
- Clinicians must weigh the improved quality of life against the higher bleeding risk when considering stents for severe post-thrombotic syndrome.
The Challenge of Advanced Post-Thrombotic Syndrome
Post-thrombotic syndrome is a frequent and debilitating complication of deep-vein thrombosis that often leaves patients with chronic limb pain, swelling, and severely impaired quality of life [1]. For patients with advanced disease driven by chronic iliac vein obstruction, standard conservative management frequently falls short, prompting growing interest in catheter-based interventions [2, 3]. While early observational data have suggested that endovascular therapy might relieve venous outflow obstruction and mitigate symptoms, rigorous randomized trial data have been lacking [4]. Furthermore, balancing the potential benefits of these procedures against the bleeding risks of the necessary antithrombotic regimens remains a persistent clinical challenge [5]. A new randomized trial now offers much-needed clarity on the efficacy and safety of endovascular interventions for this difficult-to-treat population, providing physicians with concrete data to guide treatment decisions.
Stenting and Enhanced Antithrombotics: Trial Design
To evaluate the efficacy of catheter-based interventions, researchers conducted the C-TRACT trial (ClinicalTrials.gov number NCT03250247), a study funded by the National Heart, Lung, and Blood Institute and other organizations. The trial randomly assigned 225 patients who had moderate or severe post-thrombotic syndrome and imaging-confirmed iliac-vein obstruction. Participants were allocated to receive either standard post-thrombotic syndrome care alone or standard care combined with endovascular therapy. For those in the intervention arm, the endovascular therapy specifically consisted of iliac-vein stent placement paired with enhanced antithrombotic therapy.
The investigators established the severity of post-thrombotic syndrome at 6 months as the primary outcome. To ensure objective measurement, blinded evaluators assessed symptom severity using the validated Venous Clinical Severity Score (VCSS), a clinical instrument that quantifies the physical signs of venous disease on a scale ranging from 0 to 30, with higher scores indicating more severe manifestations. Beyond the primary symptom severity endpoint, the researchers also tracked key secondary outcomes, which included both venous disease-specific quality of life and overall quality of life.
Significant Reductions in Symptom Severity
At the 6-month follow-up, patients who underwent iliac-vein stenting demonstrated a statistically significant reduction in symptom severity compared to those receiving standard care alone. The study found that the mean (±SD) VCSS was 8.1±5.1 in the endovascular-therapy group versus 10.0±4.9 in the standard care group. This yielded an adjusted difference in VCSS between the two groups of -2.0 (P=0.001). For clinicians managing these patients, this reduction reflects a measurable decrease in the daily burden of limb pain, swelling, and skin changes associated with chronic venous obstruction.
Beyond symptom reduction, the researchers evaluated functional benefits using two distinct scales to measure patient well-being. Venous disease-specific quality of life was assessed with the Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire, a tool scored from 0 to 100 that captures the specific impact of leg symptoms on daily activities. On this metric, venous disease-specific quality of life improved more in the endovascular group at 6 months, showing an adjusted difference of 14.5 points (P<0.001) over the standard care group. Similarly, overall quality of life was assessed with the Medical Outcomes Study 36-Item Short-Form Health Status Survey physical component summary score, which also ranges from 0 to 100. The data showed that overall quality of life improved more in the endovascular group at 6 months, with an adjusted difference of 6.1 points (P<0.001). These improvements indicate that restoring venous outflow through stenting translates directly into enhanced daily activity and better overall physical health for patients with advanced post-thrombotic syndrome.
Weighing Clinical Benefits Against Bleeding Risks
While the clinical and functional improvements are clear, physicians must weigh these benefits against the safety profile of the intervention. The enhanced antithrombotic regimen required to maintain stent patency carries a measurable cost. Through 6 months, bleeding occurred in 11.6% of the endovascular-therapy group compared to 3.6% of the standard care group (P=0.03). This statistically significant increase highlights the need for careful patient selection and close monitoring when prescribing the aggressive anticoagulation protocols necessary for endovascular interventions.
Ultimately, the findings demonstrate that endovascular therapy reduced symptom severity and improved quality of life over 6 months but increased bleeding risk. For practicing clinicians managing moderate or severe post-thrombotic syndrome with iliac-vein obstruction, these results clarify the therapeutic trade-offs. Iliac-vein stenting offers an effective strategy to alleviate chronic limb impairment and restore daily function, provided that the patient is an appropriate candidate who can safely tolerate the elevated risk of bleeding associated with the required antithrombotic therapy.
References
1. Weinberg I, Vedantham S, Salter A, et al. Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. Vascular Medicine. 2019. doi:10.1177/1358863x19862043
2. Vedantham S, Kahn SR, Goldhaber SZ, et al. Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. Vascular Medicine. 2016. doi:10.1177/1358863x16650747
3. Vedantham S, Kahn SR, Goldhaber SZ, et al. Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel.. Vascular medicine (London, England). 2016. doi:10.1177/1358863X16650747
4. Li M, Wang S, Zhao J, Li C, Yan Y, Shi C. Iliac vein stenting outcomes in non-thrombotic and thrombotic diseases: A systematic review and meta-analysis. 2025. doi:10.17305/bb.2025.12777
5. Gorog DA, Gue YX, Chao T, et al. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thrombosis and Haemostasis. 2022. doi:10.1055/s-0042-1750385
